Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: a 24-week, multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Soo Heon KwakKyung Ah HanKyung-Soo KimJae Myung YuEunSook KimJong Chul WonJun Goo KangChoon Hee ChungSeungjoon OhSung Hee ChoiKyu Chang WonSin Gon KimSeung Ah ChoBo Young ChoKyong Soo ParkPublished in: Diabetes, obesity & metabolism (2023)
Monotherapy with enavogliflozin 0.3 mg improved glycaemic control in people with T2DM. Enavogliflozin therapy also exerted beneficial effects on body weight, blood pressure, and lipid profile. This article is protected by copyright. All rights reserved.
Keyphrases
- phase iii
- placebo controlled
- double blind
- body weight
- blood pressure
- clinical trial
- phase ii
- study protocol
- open label
- type diabetes
- phase ii study
- hypertensive patients
- heart rate
- combination therapy
- randomized controlled trial
- glycemic control
- stem cells
- squamous cell carcinoma
- blood glucose
- bone marrow
- cell therapy
- metabolic syndrome
- cross sectional